The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

Abstract

Objective.-To provide healthcare professionals with updated guidance in the use of novel preventive and acute treatments for migraine in adults.Background.-The principles of preventive and acute pharmacotherapy for patients with migraine have been outlined previously, but the emergence of new technologies and treatments, as well as new formulations of previously established treatments, has created a need for an updated guidance on the preventive and acute treatment of migraine.Methods.-This statement is based on a review of existing guidelines and principles for preventive and acute treatment of migraine, as well as the results of recent clinical trials of drugs and devices for these indications. Input was sought from health insurance providers, employers, pharmacy benefit service companies, device manufacturers, pharmaceutical and biotechnology companies, patients, and patient advocates. Expert clinicians and researchers in the field of headache medicine from across North America and the European Union provided input and feedback.Results.-The principles of pharmacologic preventive treatment of migraine with oral treatments have been as follows: use evidence-based treatments when possible and appropriate; start with a low dose and titrate slowly; reach a therapeutic dose if possible; allow for an adequate treatment trial duration; establish expectations of therapeutic response and adverse events; and maximize adherence. Newer injectable treatments may work faster and may not need titration. The principles of acute treatment include: use evidence-based treatments when possible and appropriate; treat early after the onset of a migraine attack; choose a nonoral route of administration for selected patients; account for tolerability and safety issues; consider self-administered rescue treatments; and avoid overuse of acute medications. Neuromodulation and biobehavioral therapy may be appropriate for preventive and acute treatment, depending on the needs of individual patients. Neuromodulation may be useful for patients who prefer nondrug therapies or who respond poorly, cannot tolerate, or have contraindications to pharmacotherapy.Conclusions.-This statement updates prior recommendations and outlines the indications for initiating, continuing, combining, and switching preventive and acute treatments of migraine.

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

“…The drug was provided for patients with migraine with or without aura diagnosed by expert physicians according to the International Classification of Headache Disorders (ICHD) criteria [2]. All the study patients had to have > 4 monthly migraine days and failure of ≥2 prior preventive treatments for migraine, according to the eligibility criteria established by the European Headache Federation [14] and the American Headache Society [25]. Due to the limited availability of the drug, the study centers focused on the most difficult-to-treat patients, i.e.…”

Third Window Syndrome: Surgical Management of Cochlea-Facial Nerve Dehiscence

“…This model is based upon the distribution of the neuropeptide calcitonin-gene-related-peptide (CGRP), which has a complex distribution within the vestibular periphery (74). One must acknowledge that the use of CGRP-binding monoclonal antibodies as biologics in the clinical practice of migraine management (75,76) has a potential to produce a side effect of peripheral vestibular dysfunction or injury due to the impairment of vestibular efferent function.…”

Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain

“…The treatment of primary headache disorders is challenging, requiring both acute and preventive therapeutic measures [57,58]. The preventive treatment aims to reduce the frequency, severity and duration of headaches, and to avoid medication-overuse headache.…”